Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract |
(b) Provide in the abstract an informative and balanced summary of what was done and what was found | ||
Introduction |
|
|
Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported |
Objectives | 3 | State specific objectives, including any prespecified hypotheses |
Methods |
|
|
Study design | 4 | Present key elements of study design early in the paper |
Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection |
Participants | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants |
Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable |
Datasources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group |
Bias | 9 | Describe any efforts to address potential sources of bias |
Study size | 10 | Explain how the study size was arrived at |
Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why |
Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding |
(b) Describe any methods used to examine subgroups and interactions | ||
(c) Explain how missing data were addressed | ||
(d) If applicable, describe analytical methods taking account of sampling strategy | ||
(e) Describe any sensitivity analyses | ||
Results |
|
|
Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed |
(b) Give reasons for non-participation at each stage | ||
(c) Consider use of a flow diagram | ||
Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders |
(b) Indicate number of participants with missing data for each variable of interest | ||
Outcome data | 15* | Report numbers of outcome events or summary measures |
Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included |
(b) Report category boundaries when continuous variables were categorized | ||
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |